# Nuclide record f-18-fet (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/f-18-fet/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "f-18-fet" ;
  schema:name "Floretyrosine F-18 (FET)"@en ;
  schema:alternateName "18F-FET"@en, "O-(2-[18F]fluoroethyl)-L-tyrosine"@en, "Pixclara"@en, "TLX101-Px"@en, "Pixclara" ;
  schema:description "A brain-tumour PET tracer that shows where active tumour tissue is by how much it grabs a labelled amino acid, which helps tell a true regrowing tumour apart from scan changes caused by past treatment. Approved by the FDA in September 2026, the first scan of its kind cleared for this use in the US."@en ;
  schema:url <https://nuclide.cc/drugs/f-18-fet/> ;
  schema:dateModified "2026-09-27"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218592>, <https://telixpharma.com/wp-content/uploads/2026/09/USPI_PIXCLARA_Sep2026.pdf>, <https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6351513/> ;
  nuclide:status "approved" ;
  nuclide:tag "amino acid PET", "glioma", "newly approved" ;
  nuclide:modality "PET tracer" ;
  nuclide:approval "US 2026: Use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients 1 month of age and older" ;
  nuclide:related <https://nuclide.cc/drugs/f-18-fdopa/>, <https://nuclide.cc/isotopes/f-18/> ;
  nuclide:indications <https://nuclide.cc/indications/glioblastoma/> ;
  nuclide:technologies <https://nuclide.cc/technologies/pet/>, <https://nuclide.cc/technologies/pet-ct/> ;
  nuclide:companies <https://nuclide.cc/companies/telix/> .